



## Immunotherapy: tumor engraftment & efficacy assessment

- Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment
- Marín-Jiménez JA, et al. Front Immunol. 2021*
- Tentler JJ, et al. BMC Cancer. 2020*
- Capasso A, et al. J Immunother Cancer. 2019*
- Gammelgaard OL, et al. Mol Oncol. 2018*

## Oncology: chemotherapy, radiotherapy, non-immune therapy

- Capasso A, et al. J Immunother Cancer. 2019*
- Marín-Jiménez JA, et al. Front Immunol. 2021*

## Vaccines

Contact us for more information

## Cell-based therapy: CAR-T cells

- Valton J, et al. Sci Rep. 2018*

## Translatability to patient

- Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model
- Lang J, et al. J Clin Endocrinol Metab. 2020*

## Safety & Toxicology Studies

- Cytokine Release Syndrome: Chasing the storm in BRGSF-HIS
- Deciphering High-Dose IL-2 Toxicity in Reconstituted HIS Mice
- Li Y, et al. Nat Commun. 2017*

## Autoimmune diseases

Contact us for more information

## Host-pathogen interactions

- Coleman CB, et al. J Virol. 2018*
- Li Y, et al. Nat Methods. 2018*

## Alloreactivity: GvHD & transplant rejection

Contact us for more information

## Antisense oligonucleotide (ASO)-based therapy

Contact us for more information

Resistant to irradiation

Long lifespan/  
broad therapeutic window